Navigation Links
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Date:1/23/2008

(endometrium). The American Cancer Society estimates that there will be approximately 39,000 new cases of cancer of the uterine body diagnosed in the U.S. in 2007, resulting in approximately 7,400 deaths. There are currently four basic types of treatment for endometrial cancer including surgery, radiation, hormone therapy, and chemotherapy, of which surgery is the most common treatment.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forw
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
8. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015  Essilor is pleased to announce the launch ... the eyestrain that comes with the constant connection to ... an everyday pair of glasses to provide comfort and ... smart phones, tablets and computers for hours at a ... a prescription but also those who currently wear contact ...
(Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
(Date:9/4/2015)... DUBLIN , Sept. 4, 2015  Allergan plc (NYSE: ... that Brent Saunders , CEO and President of Allergan, ... at the Morgan Stanley Global Healthcare Conference 2015 in ... http://photos.prnewswire.com/prnh/20150612/222796LOGO The presentation will take ... Time at the Grand Hyatt New York, 109 East 42nd ...
Breaking Medicine Technology:Essilor Launches New Eyezen Glasses Specifically Designed For A Digital Focused Audience 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3
... , SUNNYVALE, Calif., Dec. 3 ... focused on developing and commercializing innovative small molecule drugs for ... that it will host a webcast and conference call on, ... Time and 8:00am Pacific Time) to discuss clinical data regarding ...
... ... MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November ... Connect.PACS(TM) product, enabling the first radiology informatics capabilities ... newly branded Certegra(TM) Informatics Platform . , ...
Cached Medicine Technology:Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3
(Date:9/4/2015)... , ... September 04, 2015 , ... ... the surrounding communities, is launching a charity effort to provide for the family ... to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today ... meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. ... in the consumer goods industry, it can be difficult for companies to navigate, ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... separate “Partner of the Year” awards at this year’s Microsoft Worldwide Partner Conference ... 2015 “Partner of the Year” Award Winner for Data Platform services, the 2015 ...
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic dentist ... CEREC is a newer method for creating restorations through innovative imaging equipment and ... the need for multiple appointments, CEREC produces restorations with total precision for a ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy ... compete in the Ironman World Championships in Kona on October 10th. , Mike is ... Brain Injury (TBI) through combat and the cutting-edge treatments that restore their quality of ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... Scientists hope to make it available online, BOSTON, ... discovered a simple and inexpensive way for patients with,retinal ... in their vision,loss. In a study published in this ... compelling visual illusion known as the induced twinkle,after-effect (TAE) ...
... 24 Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) ... six months of fiscal 2008, ended September 30, 2007, ... $28.3 million,and $53.0 million for the corresponding periods of ... over second quarter and first six,months of fiscal 2007, ...
... Expenses ... for Medical Foods, NOVATO, Calif., ... that it has,provided a $250,000 grant to the National Organization for ... with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from this,new program ...
... IRVINE, Calif., Oct. 24 CME LLC ... medical education programs,since 1978, today announced it has ... Association (APA) as an approved sponsor of,continuing medical ... the five-year full approval as part of the ...
... Calif., October 24, 2007 The Parkinsons Institute and ... treatment reduces medication-induced dyskinesias by as much as 50 ... senior research scientist, Maryka Quik, Ph.D., the research will ... of Neurology. , Levodopa, the most common ...
... 24 Anesiva,Inc. (Nasdaq: ANSV ) will announce ... close on Thursday, November 1, 2007 and will hold ... of Anesiva,s,management team will discuss financial results from the ... the company,s product pipeline, recent,events and milestones. Interested ...
Cached Medicine News:Health News:'Twinkle After-Effect' Can Help Retinal Patients Detect Vision Loss Quickly and Cheaply and Prevent Further Loss 2Health News:'Twinkle After-Effect' Can Help Retinal Patients Detect Vision Loss Quickly and Cheaply and Prevent Further Loss 3Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 2Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 3Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 4Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 5Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 6Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:CME LLC Granted Five-Year Full Approval by the American Psychological Association 2Health News:Parkinson's Institute research shows that nicotine reduces levodopa-induced dyskinesias 2Health News:Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007 2
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
... The SPOTCHEM EZ is a small bench ... Testing is performed on reagent strips with results ... is 48 tests per hour. The instrument accepts ... the swipe of a magnetic card. At the ...
... Veriteq's Refrigerator and Freezer Monitoring ... monitoring system for refrigerators and ... install. Using a building's existing ... Freezer monitoring solution automates the ...
The ThermaViewer™ is constructed and engineered for use in laboratories, hospitals, and commercial kitchens to monitor and document freezer and refrigerator temperatures where inventory is store...
Medicine Products: